Table 1.
Baseline characteristics of 375 HIV-1-positive patients treated with first-line ARV regimens in Gabon
| Variables | Women (n=277) | Men (n=98) | Total (n=375a) |
|---|---|---|---|
| Age | |||
| Median, years (IQR) | 40.8 (34.5–46.9) | 47.7 (41.5–53.2) | 42.2 (35.8–48.9) |
| HIV V3 serotyping, n (%) | |||
| HIV-1 M | 266 (96.0) | 93 (94.9) | 359 (95.7) |
| HIV-1 O | 1 (0.4) | 0 | 1 (0.3) |
| HIV-1 N | 0 | 0 | 0 |
| HIV-1 P | 0 | 0 | 0 |
| HIV-2 | 0 | 0 | 0 |
| Negativeb | 10 (3.6) | 5 (5.1) | 15 (4.0) |
| First-line ARV regimen, n (%) | |||
| D4T/AZT/ABC+3TC+NVP/EFVc | 263 (94.9) | 94 (95.9) | 357 (95.2) |
| 2 NRTIs (D4T/AZT/DDI/3TC/ABC)+1 PId | 11 (4.0) | 3 (3.1) | 14 (3.7) |
| TDF+3TC+EFV | 3 (1.1) | 1 (1.0) | 4 (1.1) |
| Time on ART (months) | |||
| 12–23 | 84 (30.3) | 27 (27.6) | 111 (29.6) |
| 24–35 | 71 (25.6) | 20 (20.4) | 91 (24.3) |
| ≥36 | 122 (44.1) | 51 (52.0) | 173 (46.1) |
| Median (IQR) | 32.3 (20.6–49.7) | 35.4 (21.3–50.9) | 33.6 (21.2–50.4) |
| Unstructured treatment interruptions | |||
| n (%) | 122 (44.0) | 40 (40.8) | 162 (43.2) |
| Duratione, median (IQR) (months) | 6 (2–13) | 10 (6–21) | 7 (3–15) |
| Recurrent events (n) | 43/119 (36.1) | 13/43 (30.2) | 56/162 (34.6) |
| CD4+ count at ART initiation | |||
| Median, cells/µl (IQR) | 158 (76–249) | 164 (65–247) | 159 (70–248) |
| CD4+ count at enrolment | |||
| Median, cells/µl (IQR) | 334 (217–501) | 343 (202–484) | 337 (215–492) |
a
Including 300 patients from the semirural centre (Franceville) and 75 from the rural centre (Koulamoutou).
b
The 15 samples found negative with the V3 serotyping HIV ELISA were found positive by HIV-1 western blot (New Lav Blot I, Bio-Rad, Marnes-La-Coquette, France).
c
D4T(n=121/)/AZT(n=215)/ABC(n=21)+3TC+NVP(n=78)/EFV(n=279).
d
IDV, n=6; NFV, n=4; LPV/r, n=4.
e
The duration of unstructured TIs was recorded for 101 patients.
Abbreviations: ART, antiretroviral therapy; D4T, stavudine; ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; IDV, indinavir; ABC, abacavir; DDI, didanosine; LPV/r, ritonavir-boosted lopinavir.